Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 14/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3527537 | 0.83 | NAMPT (0.53) | NAMPTCYP3A4CYP2C9DRD2TLR9 | |
| SCHEMBL4403152 | 0.78 | LIPE (0.48) | NAMPTCYP3A4CYP2C9TLR9TLR8 | |
| SCHEMBL27721037 | 0.77 | NAMPT (0.43) | NAMPTCYP3A4CYP2C9TLR9TLR8 | |
| SCHEMBL8986417 | 0.77 | NAMPT (0.65) | NAMPTPTPN2PTPN1PTPN6MAPT | |
| SCHEMBL10156800 | 0.76 | NAMPT (0.60) | NAMPTCYP2C9PTPN2PTPN1PTPN6 | |
| SCHEMBL13216129 | 0.76 | NAMPT (0.58) | NAMPTCYP3A4CYP2C9PTPN2PTPN1 | |
| SCHEMBL16994796 | 0.76 | TLR9 (0.51) | MAPTDRD2TLR9TLR8TLR7 | |
| SCHEMBL22852497 | 0.75 | NAMPT (0.47) | NAMPTPTPN2PTPN1PTPN6CHRM1 | |
| SCHEMBL612556 | 0.75 | ESR2 (0.47) | NAMPTPTPN2PTPN1PTPN6CHRM1 | |
| SCHEMBL3006555 | 0.75 | NAMPT (0.52) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642270-B2 | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-05 | — | — | US | disclosed |
| EP-1937681-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007033232-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | FLT3, FES, FGR | NAMPT 2198/4885CYP3A4 3320/4885CYP2C9 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.